There are currently 95 clinical trials in Chandler, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, Chandler Regional Medical Center, Arizona Eye Center and Ironwood Cancer and Research Centers. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
NCT03072927
Recruiting
This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Arizona Specialty Surgery Center, Chandler, Arizona +1 locations
Conditions: Lumbar Spinal Stenosis
Register for Updates
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
NCT05135286
Recruiting
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Gender:
All
Ages:
Between 45 years and 80 years
Trial Updated:
04/22/2024
Locations: Visus Therapeutics Investigative Site, Chandler, Arizona
Conditions: Presbyopia
Register for Updates
Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia
NCT05345561
Recruiting
A prospective, non-interventional, natural history study to assess the occurrence of higher FNAIT risk across a broad population of different racial and ethnic characteristics and the occurrence of HPA-1a alloimmunization in these women.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: New Horizons Clinical Trials, LLC, Chandler, Arizona
Conditions: Fetal and Neonatal Alloimmune Thrombocytopenia
Register for Updates
A Study to Evaluate Safety and Efficacy of a New Formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution in Patients With Dry Eye Disease
NCT06244316
Recruiting
The purpose of this study is to evaluate the safety and efficacy of two different concentrations of the new formulation of rhNGF ophthalmic solution versus vehicle, in order to demonstrate superiority of at least one of the two concentrations over vehicle in the improvement of ocular symptoms of dry eye in participants with dry eye disease (DED). The rhNGF ophthalmic solution, or vehicle, will be administered as one drop in each eye, three times a day, for 4 weeks. Participants will attend a tot... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Arizona Eye Center, Chandler, Arizona
Conditions: Dry Eye Disease
Register for Updates
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
NCT04641143
Recruiting
The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/17/2024
Locations: Metropolitan Neuro Behavioral Institute, Chandler, Arizona
Conditions: Obsessive-Compulsive Disorder
Register for Updates
An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer
NCT05592483
Recruiting
This study will collect real-world clinical and patient reported outcomes (PRO) and diary data from eligible patients with documented Human Epidermal Growth Factor Receptor 2 (HER2+) [globally] or HER2-low [North America only] in routine clinical practice.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
04/17/2024
Locations: Research Site, Chandler, Arizona
Conditions: Breast Cancer
Register for Updates
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308
Recruiting
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Ironwood Cancer & Research Centers, Chandler, Arizona
Conditions: Breast Neoplasms, Neoplasm Metastasis
Register for Updates
The Syn-Sleep Study
NCT05757206
Recruiting
In collaboration with approximately 8 centers that specialize in iRBD we will recruit a total of 80 individuals for the study. All subjects will be enrolled into a 2-year longitudinal study where skin biopsies will be performed at 3 sites on each patient at 12-month intervals (baseline, year 1, year 2). Plasma blood collection will be performed at 12-month intervals (baseline, year 1, year 2). Detailed quantified examination, cognitive evaluation, medical history, and questionnaires will be perf... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/10/2024
Locations: MD First Research, Chandler, Arizona
Conditions: REM Sleep Behavior Disorder (iRBD)
Register for Updates
AMPLATZER PFO Occluder Post Approval Study
NCT03309332
Recruiting
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
04/08/2024
Locations: Chandler Regional Medical Center, Chandler, Arizona
Conditions: Stroke, Patent Foramen Ovale
Register for Updates
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
NCT04391595
Recruiting
This trial is an open-label, multicenter, Phase 0/2 trial that will enroll up to 50 participants with recurrent glioblastoma which are schedule for resection. In the lead-in cohort, a total of 10 participants will be enrolled into the proposed phase 0 clinical trial. Participants will be administered LY3214996 plus Abemaciclib prior to surgical resection of their tumor. If positive PK results are demonstrated in ≥50% of Phase 0 participants and at least 5 participants are enrolled into Phase 2,... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Chandler Regional Medical Center, Chandler, Arizona
Conditions: Glioblastoma, GBM, Glioma
Register for Updates
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222
Recruiting
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Arizona Liver Health - Chandler, Chandler, Arizona
Conditions: NASH, Cirrhosis, Liver
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Chandler Regional Medical Center, Chandler, Arizona
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates